Humana (NYSE:HUM) Stock Rating Lowered by Wall Street Zen

Humana (NYSE:HUM) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Other analysts have also recently issued reports about the stock. Oppenheimer raised their target price on shares of Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a report on Thursday, May 1st. Cantor Fitzgerald restated a “neutral” rating and set a $290.00 target price on shares of Humana in a report on Thursday, May 1st. Guggenheim began coverage on shares of Humana in a report on Wednesday, April 9th. They set a “buy” rating and a $326.00 target price for the company. Truist Financial reduced their target price on shares of Humana from $325.00 to $305.00 and set a “hold” rating for the company in a report on Monday, May 12th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating for the company in a report on Tuesday, February 18th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $284.24.

Humana Stock Performance

Shares of HUM opened at $234.87 on Friday. The firm has a 50-day moving average price of $250.43 and a 200 day moving average price of $262.41. The firm has a market capitalization of $28.35 billion, a PE ratio of 23.60, a P/E/G ratio of 2.05 and a beta of 0.43. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a 52-week low of $212.45 and a 52-week high of $406.46.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. The firm had revenue of $32.11 billion during the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. Humana’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $7.23 EPS. On average, sell-side analysts anticipate that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of HUM. FPC Investment Advisory Inc. bought a new position in shares of Humana during the 4th quarter valued at $27,000. Centricity Wealth Management LLC bought a new position in shares of Humana during the 4th quarter valued at $30,000. Cary Street Partners Investment Advisory LLC raised its holdings in shares of Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock valued at $31,000 after purchasing an additional 46 shares in the last quarter. LFA Lugano Financial Advisors SA raised its holdings in shares of Humana by 56.3% during the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 45 shares in the last quarter. Finally, OFI Invest Asset Management bought a new position in shares of Humana during the 4th quarter valued at $33,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.